GlassScriptPhysician profile
Charles Alexander Dasher
NPI 1851552111
$6,440.76
in general payments reported to CMS, 2019-2025
28 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $443 · 2021: $657 · 2022: $833 · 2023: $785 · 2024: $1,686 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,792 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,791.92 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,396.80 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,364.97 | 2019-2025 | Linzess, Rinvoq |
| Celgene Corporation | $539.52 | 2021-2024 | Zeposia |
| Pfizer INC. | $522.71 | 2019-2025 | |
| Ardelyx, INC. | $411.03 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $318.64 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $311.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $213.09 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $209.72 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.24 | 2020-2024 | Xifaxan |
| Gilead Sciences, INC. | $171.07 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $113.70 | 2021 | |
| Romark Laboratories, Lc | $109.08 | 2020 | |
| Redhill Biopharma INC. | $108.74 | 2022 | |
| Genzyme Corporation | $90.81 | 2022-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.69 | 2020-2021 | |
| Boston Scientific Corporation | $81.17 | 2019-2023 | Captivator II |
| Celltrion USA INC. | $59.72 | 2024-2025 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $32.18 | 2020-2023 | Linzess |
| Allergan, INC. | $30.41 | 2019 | |
| Enterra Medical, INC. | $29.99 | 2022 | |
| Organon LLC | $24.24 | 2023 | Hadlima |
| Aimmune Therapeutics, INC. | $18.31 | 2024 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Dasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.